Article
The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients.
Clinical transplantation - 1 May 2014
Schoeppler Kelly E, Aquilante Christina L, Kiser Tyree H, Fish Douglas N, Zamora Martin R
Abstract excerpt
Everolimus (EVR) has inter-individual pharmacokinetic (PK) variability and a narrow therapeutic index. The study objective was to determine whether genetic polymorphisms, co-medications, and/or demographic variables accounted for inter-individual variability in EVR PK in lung transplant recipients (LTxR). LTxR were genotyped for ABCB1 c.1236C>T, ABCB1 c.2677G>T/A, ABCB1 c.3435C>T, CYP3A4*1B, CYP3A5*3,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.